283 related articles for article (PubMed ID: 15780548)
1. Knowledge of and interest in hepatitis C treatment at a methadone clinic.
Walley AY; White MC; Kushel MB; Song YS; Tulsky JP
J Subst Abuse Treat; 2005 Mar; 28(2):181-7. PubMed ID: 15780548
[TBL] [Abstract][Full Text] [Related]
2. Hazardous alcohol consumption and other barriers to antiviral treatment among hepatitis C positive people receiving opioid maintenance treatment.
Watson B; Conigrave KM; Wallace C; Whitfield JB; Wurst F; Haber PS
Drug Alcohol Rev; 2007 May; 26(3):231-9. PubMed ID: 17454012
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of hepatitis B and C infection in a methadone clinic population: implications for hepatitis B vaccination.
Carter H; Robinson G; Hanlon C; Hailwood C; Massarotto A
N Z Med J; 2001 Jul; 114(1136):324-6. PubMed ID: 11548096
[TBL] [Abstract][Full Text] [Related]
4. Knowledge about Hepatitis-C among methadone maintenance treatment patients in Israel.
Cohen-Moreno R; Schiff M; Levitt S; Bar-Hamburger R; Strauss S; Neumark Y
Subst Use Misuse; 2010; 45(1-2):58-76. PubMed ID: 20025439
[TBL] [Abstract][Full Text] [Related]
5. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia.
Doab A; Treloar C; Dore GJ
Clin Infect Dis; 2005 Apr; 40 Suppl 5():S313-20. PubMed ID: 15768340
[TBL] [Abstract][Full Text] [Related]
6. Prescription opioid abuse among enrollees into methadone maintenance treatment.
Rosenblum A; Parrino M; Schnoll SH; Fong C; Maxwell C; Cleland CM; Magura S; Haddox JD
Drug Alcohol Depend; 2007 Sep; 90(1):64-71. PubMed ID: 17386981
[TBL] [Abstract][Full Text] [Related]
7. Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs.
Treloar C; Hull P; Dore GJ; Grebely J
Drug Alcohol Rev; 2012 Nov; 31(7):918-24. PubMed ID: 22612899
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment.
Backmund M; Reimer J; Meyer K; Gerlach JT; Zachoval R
Clin Infect Dis; 2005 Apr; 40 Suppl 5():S330-5. PubMed ID: 15768343
[TBL] [Abstract][Full Text] [Related]
9. Management of hepatitis C among drug users attending general practice in Ireland: baseline data from the Dublin area hepatitis C in general practice initiative.
Cullen W; Stanley J; Langton D; Kelly Y; Bury G
Eur J Gen Pract; 2007; 13(1):5-12. PubMed ID: 17366287
[TBL] [Abstract][Full Text] [Related]
10. Methadone maintenance treatment (MMT) in general practice or in specialized centers: profile of patients in the Swiss Canton of Vaud.
Pelet A; Doll S; Huissoud T; Resplendino J; Besson J; Favrat B
Am J Drug Alcohol Abuse; 2007; 33(5):665-74. PubMed ID: 17891659
[TBL] [Abstract][Full Text] [Related]
11. Problem drinking in relation to treatment outcome among opiate addicts in methadone maintenance treatment.
Stenbacka M; Beck O; Leifman A; Romelsjö A; Helander A
Drug Alcohol Rev; 2007 Jan; 26(1):55-63. PubMed ID: 17364837
[TBL] [Abstract][Full Text] [Related]
12. Methadone maintenance patients' knowledge, attitudes, beliefs, and experiences concerning treatment for hepatitis C virus infection.
Canfield KM; Smyth E; Batki SL
Subst Use Misuse; 2010 Mar; 45(4):496-514. PubMed ID: 20141461
[TBL] [Abstract][Full Text] [Related]
13. Using latent class analysis to identify patterns of hepatitis C service provision in drug-free treatment programs in the U.S.
Strauss SM; Rindskopf DM; Astone-Twerell JM; Des Jarlais DC; Hagan H
Drug Alcohol Depend; 2006 Jun; 83(1):15-24. PubMed ID: 16289523
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy.
Hallinan R; Byrne A; Amin J; Dore GJ
J Gastroenterol Hepatol; 2005 Jul; 20(7):1082-6. PubMed ID: 15955218
[TBL] [Abstract][Full Text] [Related]
15. Physical and mental health in severe opioid-dependent patients within a randomized controlled maintenance treatment trial.
Reimer J; Verthein U; Karow A; Schäfer I; Naber D; Haasen C
Addiction; 2011 Sep; 106(9):1647-55. PubMed ID: 21489005
[TBL] [Abstract][Full Text] [Related]
16. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
[TBL] [Abstract][Full Text] [Related]
17. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities.
Litwin AH; Soloway I; Gourevitch MN
Clin Infect Dis; 2005 Apr; 40 Suppl 5():S339-45. PubMed ID: 15768345
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of an AIDS prevention education program for health service providers working with i.v. drug users.
Nelson FL; Kabacy M
J Subst Abuse; 1989; 1(4):467-70. PubMed ID: 2485292
[TBL] [Abstract][Full Text] [Related]
19. Harm reduction, hepatitis C and opioid pharmacotherapy: an opportunity for integrated hepatitis C virus-specific harm reduction.
Hallinan R; Byrne A; Dore GJ
Drug Alcohol Rev; 2007 Jul; 26(4):437-43. PubMed ID: 17564882
[TBL] [Abstract][Full Text] [Related]
20. Injecting drug users' understanding of hepatitis C.
O'Brien S; Day C; Black E; Dolan K
Addict Behav; 2008 Dec; 33(12):1602-5. PubMed ID: 18762384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
